Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brieva

Showing results (361-370 of 376) with videos related to

Pageof 38
Sort By:
Revista De Neurologia|August 27, 2013
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)Óscar Fernández, Carmen Arnal-García, Rafael Arroyo-González, et al.
Revista De Neurologia|September 21, 2013
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III)Óscar Fernández, Carmen Arnal-García, Rafael Arroyo-González, et al.
Revista De Neurologia|September 6, 2014
Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)O Fernandez, J C Alvarez-Cermeno, C Arnal-Garcia, et al.
Revista De Neurologia|September 7, 2013
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)O Fernandez, C Arnal-Garcia, R Arroyo-Gonzalez, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 7, 2017
Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimatesMaria Sepúlveda, Marta Aldea, Domingo Escudero, et al.
Multiple Sclerosis and Related Disorders|August 27, 2022
Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosisGustavo Saposnik, Sanketh Andhavarapu, Susana Sainz de la Maza, et al.
Blood|May 27, 2026
CD19 CAR T Therapy Is Feasible in Patients with Pemphigus Vulgaris Treated Without Lymphodepletion in the RESET-PV TrialDaniel Nunez, Jason Stadanlick, Thomas Furmanak, et al.
JAMA Neurology|February 27, 2023
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy DrugsEnric Monreal, José Ignacio Fernández-Velasco, María Isabel García-Sánchez, et al.
Therapeutic Advances in Neurological Disorders|November 1, 2024
Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis managementCelia Oreja-Guevara, Sergio Martínez-Yélamos, Sara Eichau, et al.
Neurologia|January 18, 2024
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023J E Meca-Lallana, S Martínez Yélamos, S Eichau, et al.
Pageof 38

Showing results (361-370 of 376) with videos related to

Sort By:
Pageof 38
Revista De Neurologia|August 27, 2013
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)Óscar Fernández, Carmen Arnal-García, Rafael Arroyo-González, et al.
Revista De Neurologia|September 21, 2013
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III)Óscar Fernández, Carmen Arnal-García, Rafael Arroyo-González, et al.
Revista De Neurologia|September 6, 2014
Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)O Fernandez, J C Alvarez-Cermeno, C Arnal-Garcia, et al.
Revista De Neurologia|September 7, 2013
Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)O Fernandez, C Arnal-Garcia, R Arroyo-Gonzalez, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 7, 2017
Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimatesMaria Sepúlveda, Marta Aldea, Domingo Escudero, et al.
Multiple Sclerosis and Related Disorders|August 27, 2022
Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosisGustavo Saposnik, Sanketh Andhavarapu, Susana Sainz de la Maza, et al.
Blood|May 27, 2026
CD19 CAR T Therapy Is Feasible in Patients with Pemphigus Vulgaris Treated Without Lymphodepletion in the RESET-PV TrialDaniel Nunez, Jason Stadanlick, Thomas Furmanak, et al.
JAMA Neurology|February 27, 2023
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy DrugsEnric Monreal, José Ignacio Fernández-Velasco, María Isabel García-Sánchez, et al.
Therapeutic Advances in Neurological Disorders|November 1, 2024
Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis managementCelia Oreja-Guevara, Sergio Martínez-Yélamos, Sara Eichau, et al.
Neurologia|January 18, 2024
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023J E Meca-Lallana, S Martínez Yélamos, S Eichau, et al.
Pageof 38